摘要
目的评估利福平注射液与口服利福平治疗初治涂阳肺结核的疗效及安全性。方法选取初治涂阳肺结核患者110例,分为治疗组(Ⅰ)(INH、舒兰新、PZA、EMB),对照组(Ⅱ)(INH,RFP,PZA,EMB口服),分别观察第一个月、第二个月痰菌好转(或阴转)率、X线好转率及药物不良反应。结果第一个月末Ⅰ、Ⅱ组的痰菌好转(或阴转)率分别为81.7%、20%(P<0.05),X线好转率分别为68.3%、20%(P<0.05);第二个月痰菌好转(或阴转)率分别为91.7%、88%(P>0.05),X线好转率分别为76.7%、64%(P>0.05);药物不良反应分别为15%、14%(P>0.05),不良反应与利福平口服剂型相同。
Objiective To evaluate the validity and security of Rifampicin in tuberculosis patients. Methods One hundred and ten new pulmonary tuberculosis patients with smear-positive were allocated into the treatment group （group I , HZE ＋ Rifampicin） and control group（group Ⅱ, HRZE）. The sputum conversion rates, chest X-ray improvement rates, and the side-effects of anti-tuberculosis drug were observed at the end of first month and second month. Result The sputum conversion rates at the end of first month in group were 81.7% ,20%, respectively （P〈 0.05） . The improving rates of chest X-ray were 68.3 %, 20% respectively （P〈0.05） . The spu- tum conversion rates at the end of second month in group were 91.7% ,88% ,respectively （P 〉0. 05）. The improving rates of chest X-ray were 76. 7% ,64%, respectively （ P 〉 0. 05 ） . The side-effect rate was 15 % in group and 14% in group （P〉0.05）. Conclusion The treatment effects regimen including Rifampicin was very satisfied. The side-effect rate by Rifampicin was the same as that of Rifampin.
出处
《临床肺科杂志》
2009年第6期748-748,825,共2页
Journal of Clinical Pulmonary Medicine
